publication date: Dec. 19, 2014

NCI Board Approves 3 Concepts

 

At a meeting Dec. 2, the NCI Board of Scientific Advisors approved three concepts during a joint meeting with the National Cancer Advisory Board.

The approved concepts are:

 

1. The Innovative Molecular Analysis Technologies Program, which supports the development, testing, and validation of high-risk and high-impact multidisciplinary, cancer-relevant technologies for the molecular and cellular analysis of cancer.

The program seeks to support technology-focused applications unlikely to be competitive through existing funding opportunities.

The program’s request for reissuance of four RFA solicitations was approved 20 to 0, with one abstention.

The four RFAs are:

Early-Stage Innovative Molecular Analysis Technology Development for Cancer Research (IMT R21)

• Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research (EMT R33)

• Early-Stage Innovative Technologies for Cancer Biospecimen Sciences (BSP R21)

• Advanced Development and Validation of Emerging Technologies for Cancer Biospecimen Sciences (BSP R33)

The RFAs will support 34 to 39 new awards per year, and would cost about $11 million in the first year.

The IMAT program, a trans-divisional initiative involving all extramural divisions of NCI as well as the Office of the Director and the Center to Reduce Cancer Health Disparities, has solicited applications every year since 1998.

To date, 3,914 applications have been received, with a total of 478 new competitive awards. As of November 2014, 97 projects are active.

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.